Pharmacokinetically based estimation of patient compliance with oral anticancer chemotherapies: In silico evaluation

Clinical Pharmacokinetics

Volumn 48, Issue 6, 2009, Pages 359-369

  Hénin, Emilie ^a   Tod, Michel ^a   Trillet Lenoir, Véronique ^a,b   Rioufol, Catherine ^a,b   Tranchand, Brigitte ^a,c   Girard, Pascal ^a  

^a UNIVERSITÉ CLAUDE BERNARD LYON 1   (France)

^b CENTRE HOSPITALIER LYON SUD   (France)

^c CENTRE LÉON BÉRARD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FLUORO BETA ALANINE; CAPECITABINE; IMATINIB;

ARTICLE; CANCER CHEMOTHERAPY; COMPUTER MODEL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; MEDICATION ERROR; MULTIPLE DRUG DOSE; PATIENT COMPLIANCE; PILL; POPULATION DISTRIBUTION; POPULATION MODEL; PREDICTION; PRIORITY JOURNAL; QUALITY CONTROL;

EID: 68249147595     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.2165/00003088-200948060-00002     Document Type: Article

References (40)

1. Liu G, Franssen E, Fitch MI, et al. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997 Jan; 15 (1): 110-5
2. Chau I, Legge S, Fumoleau P. The vital role of education and information in patients receiving capecitabine (Xeloda®). Eur J Oncol Nurs 2004; 8 (3 Suppl.): S41-53
3. Gerbrecht BM, Kangas T. Implications of capecitabine (Xeloda®) for cancer nursing practice. Eur J Oncol Nurs 2004; 8 (3 Suppl.): S63-71
4. Grober SE, Carpenter RC, Glassman M, et al. A comparison of patients' perceptions of oral cancer treatments and intravenous cancer treatments: what the health care team needs to know [abstract no. 3000]. Proc Am Soc Clin Oncol 2003; 22: 746
5. Catania C, Didier F, Sbanotto A, et al. Fully oral chemotherapy regimens: patient's or physician's preference [abstract no. 3122]. Proc Am Soc Clin Oncol 2003; 22: 777
6. Waterhouse DM, Calzone KA, Mele C, et al. Adherence to oral tamoxifen: a comparison of patient self-report, pill counts, and microelectronic monitoring. J Clin Oncol 1993 Jun; 11 (6): 1189-97
7. Partridge AH, Avorn J, Wang PS, et al. Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst 2002 May 1; 94 (9): 652-61
8. Urquhart J, De Klerk E. Contending paradigms for the interpretation of data on patient compliance with therapeutic drug regimens. Stat Med 1998 Feb 15; 17 (3): 251-67
9. Zeppetella G. How do terminally ill patients at home take their medication? Palliat Med 1999 Nov; 13 (6): 469-75
10. Iskedjian M, Einarson TR, MacKeigan LD, et al. Relationship between daily dose frequency and adherence to antihypertensive pharmacotherapy: evidence from a meta-analysis. Clin Ther 2002 Feb; 24 (2): 302-16
11. Mu S, Ludden TM. Estimation of population pharmacokinetic parameters in the presence of non-compliance. J Pharmacokinet Pharmacodyn 2003 Feb; 30 (1): 53-81
12. Cramer JA, Mattson RH, Prevey ML, et al. How often is medication taken as prescribed? A novel assessment technique. JAMA 1989 Jun 9; 261 (22): 3273-7
13. De Tullio PL, Kirking DM, Arslanian C, et al. Compliance measure development and assessment of theophylline therapy in ambulatory patients. J Clin Pharm Ther 1987 Feb; 12 (1): 19-26
14. Jonsson EN, Wade JR, Almqvist G, et al. Discrimination between rival dosing histories. Pharm Res 1997 Aug; 14 (8): 984-91
15. Pullar T, Kumar S, Tindall H, et al. Time to stop counting the tablets? Clin Pharmacol Ther 1989 Aug; 46 (2): 163-8
16. Urquhart J. The electronic medication event monitor: lessons for pharmacotherapy. Clin Pharmacokinet 1997 May; 32 (5): 345-56
17. Feldman HI, Hackett M, Bilker W, et al. Potential utility of electronic drug compliance monitoring in measures of adverse outcomes associated with immunosuppressive agents. Pharmacoepidemiol Drug Saf 1999 Jan; 8 (1): 1-14
18. Rudd P. In search of the gold standard for compliance measurement. Arch Intern Med 1979 Jun; 139 (6): 627-8
19. Levine AM, Richardson JL, MarksG, et al. Compliance with oral drug therapy in patients with hematologic malignancy. JClin Oncol 1987 Sep; 5 (9): 1469-76
20. Urquhart J. Role of patient compliance in clinical pharmacokinetics: a review of recent research. Clin Pharmacokinet 1994 Sep; 27 (3): 202-15
21. Lim LL. Estimating compliance to study medication from serum drug levels: application to an AIDS clinical trial of zidovudine. Biometrics 1992 Jun; 48 (2): 619-30
22. Rubio A, Cox C, Weintraub M. Prediction of diltiazem plasma concentration curves from limited measurements using compliance data. Clin Pharmacokinet 1992 Mar; 22 (3): 238-46
23. Pullar T, Kumar S, Chrystyn H, et al. The prediction of steady-state plasma phenobarbitone concentrations (following low-dose phenobarbitone) to refine its use as an indicator of compliance. Br J Clin Pharmacol 1991 Sep; 32 (3): 329-33
24. Vrijens B, Tousset E, Rode R, et al. Successful projection of the time course of drug concentration in plasma during a 1-year period from electronically compiled dosing-time data used as input to individually parameterized pharmacokinetic models. J Clin Pharmacol 2005 Apr; 45 (4): 461-7
25. Santschi V, Wuerzner G, Schneider MP, et al. Clinical evaluation of IDAS II, a new electronic device enabling drug adherence monitoring. Eur J Clin Pharmacol 2007 Dec; 63 (12): 1179-84
26. Duffull S, Denman M, Eccleston J, et al. WinPOPT user guide (version 1.1). Dunedin: University of Otago, 2006
27. Beal SL, Sheiner LB. The NONMEM system. Am Stat 1980; 34: 118-9
28. Beal SL, Sheiner LB. NONMEM user's guides. San Francisco (CA): NONMEM Project Group, University of California, 1992
29. Insightful Corporation. S-Plus 6 user's guide. Seattle (WA): Insightful Corporation, 2002
30. Widmer N, Decosterd LA, Csajka C, et al. Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein. Br J Clin Pharmacol 2006 Jul; 62 (1): 97-112
31. Gieschke R, Reigner B, Blesch KS, et al. Population pharmacokinetic analysis of the major metabolites of capecitabine. J Pharmacokinet Pharmacodyn 2002 Feb; 29 (1): 25-47
32. Reigner B, Blesch K, Weidekamm E. Clinical pharmacokinetics of capecitabine. Clin Pharmacokinet 2001; 40 (2): 85-104
33. Wang W, Husan F, Chow SC. The impact of patient compliance on drug concentration profile in multiple doses. Stat Med 1996Mar 30; 15 (6): 659-69
34. Girard P, Sheiner LB, Kastrissios H, et al. Do we need full compliance data for population pharmacokinetic analysis? J Pharmacokinet Biopharm 1996 Jun; 24 (3): 265-82
35. Li J, Nekka F. A pharmacokinetic formalism explicitly integrating the patient drug compliance. J Pharmacokinet Pharmacodyn 2007 Feb; 34 (1): 115-39
36. Lu J, Gries JM, Verotta D, et al. Selecting reliable pharmacokinetic data for explanatory analyses of clinical trials in the presence of possible noncompliance. J Pharmacokinet Pharmacodyn 2001 Aug; 28 (4): 343-62
37. Kshirsagar SA, Blaschke TF, Sheiner LB, et al. Improving data reliability using a non-compliance detection method versus using pharmacokinetic criteria. J Pharmacokinet Pharmacodyn 2007 Feb; 34 (1): 35-55
38. Gupta P, Hutmacher MM, Frame B, et al. An alternative method for population pharmacokinetic data analysis under noncompliance. J Pharmacokinet Pharmacodyn 2008 Apr; 35 (2): 219-33
39. Soy D, Beal SL, Sheiner LB. Population one-compartment pharmacokinetic analysis with missing dosage data. Clin Pharmacol Ther 2004 Nov; 76 (5): 441-51
40. Girard P, Blaschke TF, Kastrissios H, et al. A Markov mixed effect regression model for drug compliance. Stat Med 1998 Oct 30; 17 (20): 2313-33